Amorfix Life Sciences Ltd. (TSX:AMF) is a theranostics company developing therapeutic products and diagnostic devices targeting misfolded protein diseases including ALS, cancer, and Alzheimer's Disease. Amorfix is a pioneer in the ability to identify unique regions that are buried in normal proteins, and exposed to antibodies when proteins are aberrantly folded. These unique regions are designated Disease Specific Epitopes™ (NYSE:DSE), which can be exploited by Amorfix to develop highly specific diagnostic tools, as well as targets for therapeutics of protein misfolding diseases.
Amorfix Life Sciences' CEO is an American with a PHd and an MBA who ultimately expects Amorfix to be a large American based company trading on a large US exchange. Dr. Gundel jumped at the chance to head Amorfix , but only after he saw what products they were developing and the huge potential for their success.
With the recent significant news that the Company's proprietary ovarian cancer antibody AMF-1c-120 targets and binds to tumours in a very localized and concentrated manner when administered to live animals, Amorfix is poised to start making licensing announcements with major pharmaceutical companies across the globe. These are milestones which biotech analysts have been expecting for years.
The good news is that there still seems to be a bit of time to get in before these major milestone achievements happen. The first big announcement could include any of the following: a major pharma doing a licensing deal with Amorfix for their cancer antibody treatment, their Alzheimer's Disease diagnostic, or the Lou Gehrig's Disease (ALS) diagnostic based around the aggregated SOD1 protein that has been in development for several years.
Add to any of these licensing agreements a surprise news announcement or two, combined with competing large pharmaceuticals wanting to license the same technology so as not to fall behind the competition and Amorfix Life Sciences could be the one that gets away. Don't risk missing this! Take a flier on Amorfix Life Sciences soon! This could be the next ten-bagger in the making! And there's more to this story too!
It's one very important revelation has been developing over the past several years. Interinvest, a Global Investment Company heading by the legendary Hans Black, reported that they now have nearly 20% of the company's outstanding shares. Between purchases on the open market and support of Amorfix via some of the recent financings, Hans Black seems to be putting his money where his fund is! Do you think maybe these insiders have an idea of which announcements are expected very soon? You better believe they do! A global investment company does not just purchase shares unless they feel the value of the shares is about to go through the roof. Amorfix Life Sciences has been silently going about its work and very soon will be a name everyone is talking about. Do NOT pass up the chance of a lifetime!
Disclosure: I am long OTC:ARFXF. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.